万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
【简单介绍】
California Peptide Research提供客户的多肽合成定制服务,包括肥胖抑制素, β淀粉样肾脏髓质素肽, 内皮素, 内皮素拮抗剂【详细说明】
California Peptide Research提供客户的多肽合成定制服务,包括肥胖抑制素, β淀粉样肾脏髓质素肽, 内皮素, 内皮素拮抗剂。
| a-Secretase Substrate | 1.0 mg | 165 |
| Acetyl-Arg-(Glu-Edans)-Val-His-His-Gln-Lys-Leu-Val-Phe-(Dabcyl-Lys)-Arg-OH | ||
| a-Secretase Substrate | 5.0 mg | 655 |
| Acetyl-Arg-(Glu-Edans)-Val-His-His-Gln-Lys-Leu-Val-Phe-(Dabcyl-Lys)-Arg-OH | ||
| Abarelix | 1.0 mg | 130 |
| Acetyl-(D-Naphtyl-Ala )-(p-Chloro-D-Phenylalanine)-(Pyridyl-Ala)-Ser-(NMe-Tyr)-D-Asp-Leu-(Iso-Lys)-Pro-D-Ala-NH2 | ||
| Abarelix | 5.0 mg | 530 |
| Acetyl-(D-Naphtyl-Ala )-(p-Chloro-D-Phenylalanine)-(Pyridyl-Ala)-Ser-(NMe-Tyr)-D-Asp-Leu-(Iso-Lys)-Pro-D-Ala-NH2 | ||
| Ac-Arg-Ala-Arg-AMC | 5.0 mg | 125 |
| Acetyl-Arg-Ala-Arg-AMC | ||
| Acetyl Beta Amyloid (25-35) | 1.0 mg | 55 |
| Acetyl-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH | ||
| Acetyl Beta Amyloid (25-35) | 5.0 mg | 205 |
| Acetyl-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH | ||
| Acetyl-Ala-Arg-AMC | 10.0 mg | 110 |
| Acetyl-Ala-Arg-AMC | ||
| Acetyl-Arg-Ala-Val-AMC | 5.0 mg | 110 |
| Acetyl-Arg-Ala-Val-AMC | ||
| Acetyl-Arg-Glu-Lys-Arg-AFC | 5.0 mg | 120 |
| Acetyl-Arg-Glu-Lys-Arg-AFC | ||
| Acetyl-Arg-Gly-Phe-Phe-Pro-AFC | 5.0 mg | 140 |
| Acetyl-Arg-Gly-Phe-Phe-Pro-AFC | ||
| Acetyl-Arg-Gly-Phe-Phe-Pro-AMC | 5.0 mg | 110 |
| Acetyl-Arg-Gly-Phe-Phe-Pro-AMC | ||
| Acetyl-Arg-Ser-Leu-Lys-AMC | 5.0 mg | 110 |
| Acetyl-Arg-Ser-Leu-Lys-AMC | ||
| Acetyl-Glu-Val-Asn-Leu-AFC | 5.0 mg | 120 |
| Acetyl-Glu-Val-Asn-Leu-AFC | ||
| Acetyl-Glu-Val-Asn-Leu-AMC | 5.0 mg | 110 |
| Acetyl-Glu-Val-Asn-Leu-AMC | ||
| Acetyl-Glu-Val-Asn-Leu-pNA | 5.0 mg | 90 |
| Acetyl-Glu-Val-Asn-Leu-pNA | ||
| Acetyl-Leu-Gln-Thr-Asp-AFC | 5.0 mg | 120 |
| Acetyl-Leu-Gln-Thr-Asp-AFC | ||
| Acetyl-Leu-Leu-Arg-AMC | 5.0 mg | 110 |
| Acetyl-Leu-Leu-Arg-AMC | ||
| Acetyl-Leu-Leu-Leu-AFC | 5.0 mg | 120 |
| Acetyl-Leu-Leu-Leu-AFC | ||
| Acetyl-Lys-Gln-Lys-Leu-Arg-4-methoxy-2-naphtylamide | 5.0 mg | 120 |
| Acetyl-Lys-Gln-Lys-Leu-Arg-4-methoxy-2-naphtylamide | ||
| Acetyl-Lys-Pro-Arg-AFC | 5.0 mg | 120 |
| Acetyl-Lys-Pro-Arg-AFC | ||
| Acetyl-Lys-Pro-Arg-AMC | 5.0 mg | 110 |
| Acetyl-Lys-Pro-Arg-AMC | ||
| Acetyl-Neurotensin (8-13) | 1.0 mg | 35 |
| Acetyl-Arg-Arg-Pro-Tyr-Ile-Leu-OH | ||
| Acetyl-Neurotensin (8-13) | 5.0 mg | 105 |
| Acetyl-Arg-Arg-Pro-Tyr-Ile-Leu-OH | ||
| Acetyl-Phe-Ile-Pro-Ala-Ser-Leu-Arg-AFC | 5.0 mg | 150 |
| Acetyl-Phe-Ile-Pro-Ala-Ser-Leu-Arg-AFC | ||
| Acetyl-Phe-Ser-Arg-pNA | 5.0 mg | 90 |
| Acetyl-Phe-Ser-Arg-pNA | ||
| Acetyl-Pro-Glu-Asp-Glu-AFC | 5.0 mg | 120 |
| Acetyl-Pro-Glu-Asp-Glu-AFC | ||
| Acetyl-Pro-Leu-Ser-Ser-Ile-Phe-Ser-Arg-Ile-Gly-Asp-Pro-Arg-Lys-Gly-Asp-Glu-Val-Asp-AFC | 5.0 mg | 185 |
| Acetyl-Pro-Leu-Ser-Ser-Ile-Phe-Ser-Arg-Ile-Gly-Asp-Pro-Arg-Lys-Gly-Asp-Glu-Val-Asp-AFC | ||
| Acetyl-Ser-Asp-Lys-Pro | 5.0 mg | 35 |
| Acetyl-Ser-Asp-Lys-Pro | ||
| Acetyl-Val-Glu-Ile-Ala-AFC | 5.0 mg | 120 |
| Acetyl-Val-Glu-Ile-Ala-AFC | ||
| ACTH (1-17) human | 1.0 mg | 80 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-OH | ||
| ACTH (1-17) human | 5.0 mg | 315 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-OH | ||
| ACTH (1-24), human | 1.0 mg | 80 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH | ||
| ACTH (1-24), human | 5.0 mg | 315 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH | ||
| ACTH (1-39), rat | 1.0 mg | 205 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Val-Ala-Glu-Asn-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH | ||
| ACTH (7-38), human / Corticotropin Inhibiting Peptide (7-38) | 1.0 mg | 120 |
| Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH | ||
| ACTH (7-38), human / Corticotropin Inhibiting Peptide (7-38) | 5.0 mg | 485 |
| Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH | ||
| ADAM substrate | 1.0 mg | 230 |
| (Glu-EDANS)-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-(Dabcyl-Lys)-NH2 | ||
| ADAM substrate | 5.0 mg | 895 |
| (Glu-EDANS)-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-(Dabcyl-Lys)-NH2 | ||
| Adamantaneacetyl-[DArg0,Hyp3,Thi5,8,DPhe7] Bradykinin | 1.0 mg | 60 |
| Adamataneacetyl-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Phe-Thi-Arg-OH | ||
| Adamantaneacetyl-[DArg0,Hyp3,Thi5,8,DPhe7] Bradykinin | 5.0 mg | 210 |
| Adamataneacetyl-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Phe-Thi-Arg-OH | ||
| Adrenal Secretogranin, bovine | 5.0 mg | 155 |
| Phe-Pro-Lys-Pro-Ala-Gly-Ser-Gln-Asp-Lys-Pro-Leu-His-Asn-OH | ||
| Adrenomedullin (1-50), rat | 0.5 mg | 310 |
| Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (1-50), rat | 1.0 mg | 500 |
| Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (1-52), human | 0.5 mg | 310 |
| Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (1-52), human | 1.0 mg | 500 |
| Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (11-50), rat | 0.5 mg | 230 |
| Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (11-50), rat | 1.0 mg | 395 |
| Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (22-52), human | 0.5 mg | 160 |
| Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin (22-52), human | 1.0 mg | 240 |
| Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Agatoxin IVa ( SS Cys 4,20 / Cys 12,25 / Cys 19,36 / Cys 27 | 0.5 mg | 835 |
| Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala-OH | ||
| Agatoxin IVa ( SS Cys 4,20 / Cys 12,25 / Cys 19,36 / Cys 27 | 1.0 mg | 1525 |
| Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala-OH | ||
| Akt Substrate | 5.0 mg | 105 |
| Arg-Pro-Arg-Ala-Ala-Thr-Phe-NH2 | ||
| All D Beta Amyloid (1-40), human | 0.5 mg | 395 |
| D-Asp-D-Ala-D-Glu-D-Phe-D-Arg-D-His-D-Asp-D-Ser-Gly-D-Tyr-D-Glu-D-Val-D-His-D-His-D-Gln-D-Lys-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-D-Glu-D-Asp-D-Val-Gly-D-Ser-D-Asn-D-Lys-Gly-D-Ala-D-Ile-D-Ile-Gly-D-Leu-D-Met-D-Val-Gly-Gly-D-Val-D-Val-OH | ||
| All D Beta Amyloid (1-40), human | 1.0 mg | 685 |
| D-Asp-D-Ala-D-Glu-D-Phe-D-Arg-D-His-D-Asp-D-Ser-Gly-D-Tyr-D-Glu-D-Val-D-His-D-His-D-Gln-D-Lys-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-D-Glu-D-Asp-D-Val-Gly-D-Ser-D-Asn-D-Lys-Gly-D-Ala-D-Ile-D-Ile-Gly-D-Leu-D-Met-D-Val-Gly-Gly-D-Val-D-Val-OH | ||
| Allatostatin B2, cockroach | 1.0 mg | 105 |
| Ala-Tyr-Ser-Tyr-Val-Ser-Glu-Tyr-Lys-Arg-Leu-Pro-Val-Tyr-Asn-Phe-Gly-Leu-NH2 | ||
| Alpha Atrial Natriuretic Polypeptide (1-28), human / ANP (1- | 0.5 mg | 125 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Alpha Atrial Natriuretic Polypeptide (1-28), human / ANP (1- | 1.0 mg | 205 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Alpha MSH Ac-Nle4 c[Asp5, D-Phe7, Lys10] (4-10) amide | 1.0 mg | 60 |
| Acetyl-050-Asp-His-011-Arg-Trp-Lys-NH2 | ||
| Alpha MSH Ac-Nle4 c[Asp5, D-Phe7, Lys10] (4-10) amide | 5.0 mg | 215 |
| Acetyl-050-Asp-His-011-Arg-Trp-Lys-NH2 | ||
| Alpha MSH [D-Phe7] | 1.0 mg | 60 |
| Acetyl-Ser-Tyr-Ser-Met-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH [D-Phe7] | 5.0 mg | 215 |
| Acetyl-Ser-Tyr-Ser-Met-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH [Nle4,D-Phe7] | 1.0 mg | 60 |
| Acetyl-Ser-Tyr-Ser-050-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH [Nle4,D-Phe7] | 5.0 mg | 215 |
| Acetyl-Ser-Tyr-Ser-050-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH, Ac-NLe4c[Asp5,DNal7,Lys10](4-10) amide | 1.0 mg | 60 |
| Acetyl-050-Asp-His-038-Arg-Trp-Lys-NH2 | ||
| Alpha MSH, Ac-NLe4c[Asp5,DNal7,Lys10](4-10) amide | 5.0 mg | 215 |
| Acetyl-050-Asp-His-038-Arg-Trp-Lys-NH2 | ||
| Amylin (1-37) NH2, human / Islet Amyloid Polypeptide (IAPP), | 1.0 mg | 295 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin (1-37) NH2, human / Islet Amyloid Polypeptide (IAPP), | 5.0 mg | 1315 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin (1-37) NH2, human / Islet Amyloid Polypeptide (IAPP), | 10.0 mg | 2520 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin, rat | 0.5 mg | 135 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin, rat | 1.0 mg | 230 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amyloid Blocker | 5.0 mg | 85 |
| Acetyl-Gln-Lys-Leu-Val-Phe-Phe-NH2 | ||
| Amyloid fragment (Pro18,Asp21) (17-21) | 5.0 mg | 105 |
| Leu-Pro-Phe-Phe-Asp-OH | ||
| Amyloid precursor | 1.0 mg | 135 |
| Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-(DNP-Lys)-Arg-Arg-NH2 | ||
| Amyloid precursor | 5.0 mg | 525 |
| Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-(DNP-Lys)-Arg-Arg-NH2 | ||
| Angiotensin Fragment ( 1-7 ) Acetate | 5.0 mg | 55 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-OH | ||
| Angiotensin I [Asn1,Val5,Asn9], salmon | 1.0 mg | 30 |
| Asn-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I [Asn1,Val5,Asn9], salmon | 5.0 mg | 105 |
| Asn-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I [Val5,Asn9], bullfrog | 1.0 mg | 30 |
| Asp-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I [Val5,Asn9], bullfrog | 5.0 mg | 105 |
| Asp-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I/II (1-5) | 1.0 mg | 45 |
| Asp-Arg-Val-Tyr-Ile-OH | ||
| Angiotensin II [Sar1,Ile8] | 1.0 mg | 30 |
| 034-Arg-Val-Tyr-Ile-His-Pro-Ile-OH | ||
| Angiotensin II [Sar1,Ile8] | 5.0 mg | 100 |
| 034-Arg-Val-Tyr-Ile-His-Pro-Ile-OH | ||
| Angiotensin II, human | 5.0 mg | 35 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
| Angiotensin II-[Sar1] | 5.0 mg | 80 |
| 034-Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
| Angiotensin III, human) / Angiotensin II-[Des Asp1] | 10.0 mg | 55 |
| Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
| Angiotensinogen (1-14) Renin Substrate (porcine) | 1.0 mg | 40 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser-OH | ||
| Angiotensinogen (1-14) Renin Substrate (porcine) | 10.0 mg | 185 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser-OH | ||
| ANP (123-150), rat / ANP (6-33), rat / ANP (1-28), rat | 0.5 mg | 125 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP (123-150), rat / ANP (6-33), rat / ANP (1-28), rat | 1.0 mg | 205 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP (126-150), rat / Auriculin B, ANP (4-28), rat | 0.5 mg | 125 |
| Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP (126-150), rat / Auriculin B, ANP (4-28), rat | 1.0 mg | 205 |
| Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP (4-24), frog | 1.0 mg | 165 |
| Cys-Phe-Gly-Ser-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Met-Gly-Cys-Gly-Arg-Arg-Phe-OH | ||
| ANP Des[18-22] (4-23) amide, rat | 1.0 mg | 125 |
| Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Cys-NH2 | ||
| Antennapedia Peptide | 1.0 mg | 80 |
| Arg - Gln - Ile - Lys - Ile - Trp - Phe - Gln - Asn - Arg - Arg - Met - Lys - Trp - Lys - Lys | ||
| Apamin, bee venom (SS1-11)(SS3-15) | 0.5 mg | 105 |
| Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 | ||
| Apamin, bee venom (SS1-11)(SS3-15) | 1.0 mg | 160 |
| Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 | ||
| APP (354-371) | 1.0 mg | 135 |
| Lys-Ala-Val-Ile-Gln-His-Phe-Gln-Glu-Lys-Val-Glu-Ser-Leu-Glu-Gln-Glu-Ala-OH | ||
| APP (354-371) | 5.0 mg | 525 |
| Lys-Ala-Val-Ile-Gln-His-Phe-Gln-Glu-Lys-Val-Glu-Ser-Leu-Glu-Gln-Glu-Ala-OH | ||
| APP Beta Secretase Inhibitor | 1.0 mg | 160 |
| Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-200-Val-Ala-Glu-Phe-OH | ||
| APP gamma secretase inhibitor | 5.0 mg | 60 |
| 3-5 difluorophenacetyl-Ala-217-t-Butylester | ||
| APP gamma secretase inhibitor | 5.0 mg | 60 |
| 3-5 difluorophenacetyl-Ala-(S-Phenylglycine)-Methylester | ||
| Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-(e-Dabcyl-Lysine)-Arg-OH | 1.0 mg | 135 |
| Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-(e-Dabcyl-Lysine)-Arg-OH | ||
| Arg-Leu-Lys-Gly-Gly-AFC | 5.0 mg | 140 |
| Arg-Leu-Lys-Gly-Gly-AFC | ||
| Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH | 5.0 mg | 120 |
| Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH | ||
| Asp-Glu-Val-Asp-AFC | 5.0 mg | 120 |
| Asp-Glu-Val-Asp-AFC | ||
| Atriopeptine III, rat;ANP (127-150), rat | 0.5 mg | 115 |
| Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Atriopeptine III, rat;ANP (127-150), rat | 1.0 mg | 185 |
| Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Autocamptide-2 Related Inhibitoy Peptide | 5.0 mg | 105 |
| Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH | ||
| Autocamptide-2 Related Inhibitoy Peptide | 5.0 mg | 105 |
| Myristoyl-Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH | ||
| BAM (6-22) Quote : 6920 | 0.5 mg | 125 |
| Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-OH | ||
| BAM (6-22) Quote : 6920 | 1.0 mg | 185 |
| Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-OH | ||
| BAM 3200 Bovine Adrenal Medulla Peptide E | 0.5 mg | 175 |
| Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-OH | ||
| BAM 3200 Bovine Adrenal Medulla Peptide E | 1.0 mg | 290 |
| Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-OH | ||
| Beta Amyloid (1-16) [Gln11], human | 0.5 mg | 60 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
| Beta Amyloid (1-16) [Gln11], human | 1.0 mg | 85 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
| Beta Amyloid (1-16) [Gln11], human | 5.0 mg | 320 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
| Beta Amyloid (1-16), rat | 1.0 mg | 90 |
| Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-OH | ||
| Beta Amyloid (1-16), rat | 5.0 mg | 340 |
| Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-OH | ||
| Beta Amyloid (1-28), [Gln11], human | 0.5 mg | 95 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-OH | ||
Openbiosystems| http://www.ybiotechmall.com/enstyle/firstcatalog_3294673_Openbiosystems_1.html;
Omega| http://www.ybiotechmall.com/enstyle/firstcatalog_3294674_Omega_1.html;
Oxoid| http://www.ybiotechmall.com/enstyle/firstcatalog_3294675_Oxoid_1.html;
Origene| http://www.ybiotechmall.com/enstyle/firstcatalog_3294676_Origene_1.html;
OET| http://www.ybiotechmall.com/enstyle/firstcatalog_3294677_OET_1.html;
OEM Concept| http://www.ybiotechmall.com/enstyle/firstcatalog_3294678_OEM-Concept_1.html;
OXIS| http://www.ybiotechmall.com/enstyle/firstcatalog_3294679_OXIS_1.html;
OZ Bio| http://www.ybiotechmall.com/enstyle/firstcatalog_3294680_OZ-Bio_1.html;
OUPONT| http://www.ybiotechmall.com/enstyle/firstcatalog_3294681_OUPONT_1.html;
Pel-Freez| http://www.ybiotechmall.com/enstyle/firstcatalog_3294682_Pel-Freez_1.html;
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验The Use of Phage Display Peptide Libraries for Basic and Translational Research
Phage display is a molecular technique, whereby genes are displayed in a functional form on the outer surfaces of bacteriophages by fusion to viral coat proteins. The gene product is encoded by a plasmid contained within the virus
Origins and Development of Peptide Antibiotic Research: From Extracts to Abstracts to Contracts
Peptide antibiotic research, which in the larger sense includes protein antibiotic research, actually began during the late 19th century with the work of Ehrlich, Metchnikov, Kanthack, and Petterson. Now it has been absorbed into the fields
DNA fingerprinting - agarose gel【California Institute of Technology】
Caltech Genome Research Laboratory,California Institute of Technology http://www.tree.caltech.edu/protocols/agfp.html Restriction digests consist of: 15.75 ml ddH2O 1 µl 10 X buffer B (Boehringer Mannheim) 0.25 µl HindIII (40 U/µl) 3 µl DNA
技术资料暂无技术资料 索取技术资料





